Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $7.57 million. The enterprise value is $16.95 million.
Important Dates
The last earnings date was Wednesday, May 21, 2025, before market open.
| Earnings Date | May 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 6.67 million shares outstanding. The number of shares has increased by 27.71% in one year.
| Current Share Class | 6.67M |
| Shares Outstanding | 6.67M |
| Shares Change (YoY) | +27.71% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 6.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.12 |
| Forward PS | 0.79 |
| PB Ratio | 0.61 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.21.
| Current Ratio | 1.06 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -63.07 |
Financial Efficiency
Return on equity (ROE) is -91.05% and return on invested capital (ROIC) is -68.80%.
| Return on Equity (ROE) | -91.05% |
| Return on Assets (ROA) | -35.10% |
| Return on Invested Capital (ROIC) | -68.80% |
| Return on Capital Employed (ROCE) | -121.73% |
| Revenue Per Employee | $57,821 |
| Profits Per Employee | -$129,991 |
| Employee Count | 117 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 2.78 |
Taxes
In the past 12 months, Evogene has paid $9,000 in taxes.
| Income Tax | 9,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.31% in the last 52 weeks. The beta is 1.37, so Evogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.37 |
| 52-Week Price Change | -84.31% |
| 50-Day Moving Average | 1.15 |
| 200-Day Moving Average | 1.80 |
| Relative Strength Index (RSI) | 42.46 |
| Average Volume (20 Days) | 40,780 |
Short Selling Information
| Short Interest | 177,981 |
| Short Previous Month | 241,184 |
| Short % of Shares Out | 2.67% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, Evogene had revenue of $6.77 million and -$15.21 million in losses. Loss per share was -$2.48.
| Revenue | 6.77M |
| Gross Profit | 2.78M |
| Operating Income | -22.77M |
| Pretax Income | -21.46M |
| Net Income | -15.21M |
| EBITDA | -21.15M |
| EBIT | -22.77M |
| Loss Per Share | -$2.48 |
Full Income StatementBalance Sheet
The company has $9.85 million in cash and $2.59 million in debt, giving a net cash position of $7.26 million or $1.09 per share.
| Cash & Cash Equivalents | 9.85M |
| Total Debt | 2.59M |
| Net Cash | 7.26M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 12.40M |
| Book Value Per Share | -0.55 |
| Working Capital | 902,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.77 million and capital expenditures -$607,000, giving a free cash flow of -$21.38 million.
| Operating Cash Flow | -20.77M |
| Capital Expenditures | -607,000 |
| Free Cash Flow | -21.38M |
| FCF Per Share | -$3.20 |
Full Cash Flow StatementMargins
Gross margin is 41.06%, with operating and profit margins of -336.57% and -224.82%.
| Gross Margin | 41.06% |
| Operating Margin | -336.57% |
| Pretax Margin | -254.09% |
| Profit Margin | -224.82% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.71% |
| Shareholder Yield | -27.71% |
| Earnings Yield | -200.84% |
| FCF Yield | -282.32% |
Analyst Forecast
The average price target for Evogene is $3.50, which is 218.18% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 218.18% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Evogene has an Altman Z-Score of -12.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.72 |
| Piotroski F-Score | n/a |